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Abstract:  
Aim. This article is devoted to the problem of multiple implantation failures of the thawed embryos and the 
endometrium preparation with the application of HRT, which include estrogen medicines. The variety of estrogen 
medicines and the lack of information about their comparative effectiveness in ART programs prompted us to 
conduct a study aimed at finding the most optimal and effective estrogen medicine. For comparative analysis, we 
selected the oral forms of EV and 17β–E due to their ease of use and dosing. 
Materials and methods. The objects of the study were different according to the chemical structure of the oral forms 
of estrogen-containing medicines (EV and 17β–E) for HRT. Both are used in the process of endometrium 
preparation for the transfer of thawed embryos in patients with previous repeated implantation failures. The 
subjects of the study were the levels of expression of α-ER and markers of proliferative activity of cells (Ki-67) in the 
endometrium, echographic characteristics of the endometrium, and the amount of serum estradiol in the blood and 
the effectiveness of thawed embryo transfer performed using different forms of estrogen. 
Results. Significant differences were revealed (p<0.001), when comparing the levels of α-ER expression in the 
endometrium and the marker of endometrium proliferative activity Ki-67 under the influence of various forms of 
estrogen in the study groups. Analysis of proliferative changes in the endometrium based on the ultrasound 
examination also revealed statistically significant differences in the study groups (p<0.001). The difference was 
likewise noted in its echostructure. The analysis of the influence of various estrogen medicines on estradiol serum 
levels did not reveal any significant differences in the estradiol blood level at patients of the analyzed groups in any 
days of MP (p>0,1). The statistical analysis revealed significant differences in the frequency of positive outcomes 
(clinical pregnancy) in the study groups (χ2 = 6,40, p = 0,041, the number of degrees of freedom df = 2) with the 
best indicators in Group 2. 
Conclusions. Based on the above provided data, it can be concluded that in the framework of hormone replacement 
therapy in the preparation of the endometrium for the thawed embryo transfer at patients with previous multiple 
implantation failures, it is preferable to use the oral form of 17β–E, as compared to the oral form of EV.  
Keywords: implantation failures, frozen embryo transfer protocols, hormone replacement therapy, 17β-estradiol, 
immunohistochemistry. 
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INTRODUCTION: 
Multiple disorders of reproductive function in 
patients with multiple implantation failures of the 
thawed embryos highlight the need for endometrium 
preparation with application of hormone replacement 
therapy (HRT), which contains estrogen medicines 
[1-8]. The variety of estrogen medicines and lack of 
information about their comparative effectiveness in 
ART programs prompted us to conduct a study which 
aims at finding the optimal and most effective 
estrogen medicine. For the purposes of our 
comparative analysis, we selected the oral forms of 
estradiol valerate (EV) and 17β-estradiol (17β–E) due 
to their ease of use and dosing. 
 
Micronized 17β-E is an estrogen identical in its 
chemical structure to endogenous estradiol, which is 
the most active estrogen and exceeds the activity of 
estrone in 5-15 times. Estron is a result of hepatic 
metabolism of 17β-E, the ratio of estradiol to estron 
is 0.7. When ingestion of 2 mg 17β-E per day, its 
plasma concentration fluctuates between 293-550 
pmol/l for several hours and decreases 146-183 
pmol/l after 24 hours. The equilibrium concentration 
of estradiol in the blood plasma occurs after about 5 
days, with daily oral administration of 17β–E [9, 10]. 
EV is an ether of crystalline form 17β-E. After 
absorption in the intestine, EV is metabolized during 
the first passage through the liver to 17β-E, so it can 
be considered as a precursor of natural estrogen. In 
the course of the second passage through the liver, 
estron and estron sulfate are formed, and the ratio of 
estradiol to estron is 0.17. The maximum serum 
concentration of estradiol achieved with oral EV is 
approximately 110.2 pmol/l and is usually achieved 
within 4-9 hours after taking the drug [9].  
 
Based on the above data, we suggested the more 
effective preparation of the endometrium for the 
transfer of thawed embryos with the use of oral forms 
of the drug containing 17β–E in comparison with the 
medicine containing EV, in view of its bioidentity to 
a natural estrogen and the characteristics of its 
metabolism. 
 
MATERIAL AND METHODS:  
The oral forms of estrogen-containing medicines - 
estradiol valerate (EV) and 17β–E – are the object of 
the study. The latter two differ from each other 
according to their chemical structure and are used for 
hormone replacement therapy (HRT) while preparing 
endometrium for the transfer of thawed embryos in 
patients with previous repeated implantation failures.  
The subjects of the study comprised: levels of 
expression of α-estrogen receptors (α-ER) and 
markers of proliferative activity of cells (Ki-67) in 
the endometrium, echo graphic characteristics of the 
endometrium, and the amount of serum estradiol in 
the blood and the efficacy of cryotransfer with 
application of different forms of estrogen.  
 
Instrumental, morphological, morphometric, 
immunohistochemical, enzyme immunoassay and 
statistical methods were utilized. 
 
The study included 100 patients aged 24 to 45 years 
with two or more implantation failures of a thawed 
embryo in the history. The patients were divided into 
2 groups: 
1) Group 1 – 50 patients who received an oral form 
of estradiol valerate (EV) in a dose of 4 mg from 
2nd day of menstrual period (MP) during 
endometrium preparation for the transfer of one 
thawed embryo; 
2) Group 2 - 50 patients who received an oral form 
of 17β-estradiol (17β–E) in a dose of 4 mg from 
2nd day of MP during endometrium preparation 
for transfer of one thawed embryo. 
To assess the effect of estrogen medicines on the 
state of the endometrial receptor apparatus, all 
patients underwent an endometrial biopsy in the 
period between the  9th  and 11th  day of MP 
preceding the cycle with the transfer of the thawed 
embryo using a manual vacuum aspirator Ipas MVA 
Plus® Aspirator (USA) [11]. 
 
Preservation of materials was carried out in the 
10.0% buffered formalin solution for the purpose of 
maintaining integrity of tissues and cells. 
Subsequently, the histological materials were 
exposed to alcohols of the increasing concentration 
(50.0%, 60.0%, 70.0%, 80.0%, 96.0% and absolute 
alcohol), and were clarified in xylol. Finally, the 
materials were enclosed in paraffin as well as 
manufactured into paraffin blocks. Cuts of 4-5 
microns were taken from paraffin blocks and colored 
with hematoxylin and eosin [12].  
 
The immunohistochemical research (IHC) was 
conducted following a standard technique [12]. It 
comprised the application of paraffin blocks, 
reactants of the DAKO company, Mouse Monoclonal 
Antibodies to α-ER (a clone 1D5 DAKO, Denmark, 
RTV), Ki-67 Antibodies (a clone of MIB-1 of 
DAKO, Denmark, RTV) and grouping of CD138 
plasmocytic (sindekan-1 DAKO, Denmark, RTV). To 
analyze the results of  IHC reactions, the following 
quantitative method was used: Histochemical score 
index (H-score) was calculated using the formula 
HS=1a +2b+3c, where a is the percentage of poorly 
IAJPS 2019, 06 (04), 7815-7820                       Anna Sulima et al                      ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 7818 
painted cells, b corresponds to the percentage of 
moderately painted cells; c is equal to the percentage 
of strongly painted cells; 1, 2, 3 indicate the intensity 
of coloring expressed in points.  
 
The level of α-ER expression was estimated based on 
the H-score: a result of 0 to 10 points is considered to 
be negative, a number of 11to 100 points is observed 
as low, an outcome of 101–200 is classified as 
moderate, and a development of 201+ points is 
categorized as high [12]. The morphometric study 
also measured the percentage of Ki-67 positive cells 
in the glands and a stroma using a microscope at a 
magnification of 400x within the Software DP-SOFT 
program with subsequent statistical processing. 
Photos were made with the OLYMPUS C 5050Z 
digital camera OLYMPUS CX41 fixed on the 
microscopes with a video eyepiece of DCM-130E 
SCOPE. 
 
Blood level of estradiol was measured on the 2nd-3rd, 
6th-7th, 10th-11th, 14th-16th day of the menstrual period 
and on the day of embryo transfer (Days 19 to 21) by 
the enzymoimmunoassay (EIA) method with 
application of "DRG EIA Estradiol" reagent (closed 
joint stock company "DRG of Tekhsistems, Russia) 
ranging from 60 pmol/l up to 1655 pmol/l. Following 
the working standards and clinical recommendations 
developed for women of reproductive age in 
accordance with the menstrual period phase,  normal 
indexes were set within the following framework: the 
follicular phase — 68.0-1269.0 pmol/L, the ovulatory 
phase — 131.0-1655.0 pmol/l, the luteal phase — 
91.0-861.0 pmol/l [13]. 
 
Ultrasound assessment (ultrasound) of endometrial 
thickness and structure was performed using a series 
of longitudinal and transverse sections on the Sonix 
SP (Canada) device by convex linear vaginal multi–
frequency sensors (3.5-7.5 MHz) in the scanning 
mode in a two-dimensional gray scale (B-mode) on 
the 2nd-3rd, 6th-7th, 10th-11th, 14th-16th days of MP and 
on the day of embryo transfer (Days 19 to 21). 
 
 
For statistical data processing, the following 
programs were used: IBM SPSS 19.0, Matlab 7. The 
sampling mean (M), and the standard deviation of 
residuals (ϭ) were computed for the qualitative data 
presented in form of descriptive statistics. The latter 
value was calculated if the qualitative data 
distribution diverged from the normal values. The 
values were categorized using the Shapiro-Wilk 
test for normality. For pairwise statistical 
comparisons of qualitative data sets, with each set not 
varying from the normal distribution, the Student's 
criterion with a two-tailed critical region was used. 
To compare two empirical distributions of categorical 
data, the Pearson chi-squared test (χ2) with the 
designation of degrees of freedom (df) was applied. 
Additionally, the Fisher’s angle transform criterion 
supplemented by the Yates’ amendment (designated 
as T) was utilized for the comparison of qualitative 
dichotomizing data. In all cases, the level of 
statistical significance was designated as "р". The 
following scale was developed to measure 
significance: 
p<0.05 significant 
p<0.01 very significant 
p<0.001 highly significant [14]. 
 
RESULT AND DISCUSSION:  
Significant differences were revealed (p<0.001), 
when comparing the levels of α-ER expression in the 
endometrium and the marker of endometrium 
proliferative activity Ki-67 under the influence of 
various forms of estrogen in the study groups. In 
Group 2 there was a more prominent expression of α-
ER (207.2±1.13 points). Furthermore, markers of 
cells proliferative activity Ki-67 in the glands and 
stroma of the endometrium (37.2±0.41 and 21.1±0.49 
respectively) were observed (see Table 1). 
 
Table 1. α-estrogen receptors’ expression and Ki-67 expression in the endometrium (own representation). 
 
Group of patients 
α-estrogen 
receptors’ 
expression 
M±m 
Ki-67 expression in 
the endometrium 
gland  
M±m 
Ki-67 expression in 
the endometrium 
stroma  
M±m 
1 (50) 123,6±0,69 22,8±0,35 7,7±0,18 
2 (50) 207,2±1,13 37,2±0,41 21,1±0,49 
Value of the criterion and statistical 
significance of the differences  
t=63,10 
р <0,001 
t=26,70 
р <0,001 
t=25,50 
р <0,001 
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Analysis of proliferative changes in the endometrium (thickness, structure and growth dynamics) derived from the 
ultrasound revealed statistically significant differences in the study groups (p<0.001). The endometrial thickness 
was 4.1 ± 0.03 mm on Days 6-7 of MP in Group 1, and in Group 2 – 6.4 ± 0.04 mm. The tendency observed during 
the first ultrasound examination continued in later: on Days 10-11 and 14-16, the endometrial thickness in Group 1 
was 6.8 ± 0.04 mm, and 7.3 ± 0.03 mm, respectively, and was significantly lower compared to Group 2 - 8.2 ± 0.04 
mm, and 9.2 ± 0.03 mm, respectively (see Table 2). The difference was noted not only in the endometrium 
thickness, but also in its echo structure. In Group 2, the endometrium constituted an expressed three-layer structure 
on the Day 14 of MP upon the application of 17β-E, while in Group 1, which was using EV, these changes were less 
pronounced. 
 
Table 2. Ultrasound assessment of endometrium thickness in dynamics (own representation). 
 
Day of menstrual 
period 
Endometrium thickness (mm) 
M±m Significance of the differences 
Group 1 Group 2 
2–3  2,15 ±0,03 2,35 ±0,04 t = 4,17, р < 0,001 
6–7  4,13 ±0,03 6,37 ±0,04 t = 44,50, р < 0,001 
10–11  6,84 ±0,04 8,19 ±0,04 t = 25,00, р < 0,001 
14–16  7,27 ±0,03 9,20 ±0,03 t = 42,70, р < 0,001 
19–21 8,40 ±0,03 9,86 ±0,03 t = 31,60, р < 0,001 
 
The analysis of the influence of various estrogen drugs on estradiol serum levels did not reveal the significant 
differences in the estradiol blood level at patients of the analyzed groups on any days of the menstrual period 
(p>0,1) (see Table 3). 
Table 3. Assessment of estradiol blood level in dynamics (own representation). 
 
Day of menstrual 
period 
Estradiol blood level, pmol/l 
Significance of the 
differences Group 1 
M±m 
Group 2 
M±m 
2–3  76,14 ± 0,06 71,43 ± 0,13 р = 0,672 
6–7  325,94 ± 0,74 323,87 ± 1,1 р = 0,345 
10–11  661,18 ± 0,70 635,25 ± 0,93 р = 0,631 
14–16  1476,53 ± 0,96 1465,78 ± 0,87 р = 0,795 
19–21  793,21 ± 0,67 778,33 ± 0,79 р = 0,573 
 
The efficacy of thawed embryo transfer was evaluated on Day 21 after an embryo transfer by transvaginal 
ultrasound. The evaluation was performed in order to determine the presence and localization of the fetal egg. The 
statistical analysis revealed significant differences in the frequency of positive outcomes (clinical pregnancy) in the 
study groups (χ2 = 6,40, p = 0,041, the number of degrees of freedom df = 2) with the best indicators in Group 2 
(see Table 4). Uterine pregnancy was diagnosed in 16 patients in Group 2 (32.0%) who received the oral hormone 
replacement therapy with 17β–E on Day 21 after the embryo transfer. InGroup 1, uterine pregnancy was diagnosed 
only in 12.0 % (6) of patients treated with HRT by oral EV (see Table 4). 
 
Table 4. The thawed emryo transfer outcomes (own representation).  
 
The embryo transfer outcome Group 1 Group 2 
Implantation failure 42 (84,0 %) 31 (62,0 %) 
Biochemical pregnancy 2 (4,0 %) 3 (6,0 %) 
Clinical pregnancy 6 (12,0 %) 16 (32,0 %) 
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CONCLUSION:  
Based on the above provided data, it can be 
concluded that in the framework of hormone 
replacement therapy during the preparation of the 
endometrium for the thawed embryo transfer at 
patients with previous multiple implantation failures, 
it is preferable to use the oral form of 17β–E, 
compared with the oral form of EV. The obtained 
results are probably related to the peculiarities of the 
chemical structure and metabolism of the analyzed 
drugs. 
 
List of symbols and abbreviations:  
EIA - enzymoimmunoassay 
EV – estradiol valerate 
HRT – hormonal replacement therapy 
IHC - immunohistochemistry 
MP – menstrual period 
α-ER - α-estrogen receptor 
Ki-67 - marker of endometrium proliferative activity 
17β–E - 17β–estradiol 
 
REFERENCES:  
1. Manukhin IB, Tumilovich LG, Gevorkyan MA. 
Clinical Lectures on Gynecological 
Endocrinology [Published in Russian: 
Клинические лекции по гинекологической 
эндокринологии]. 2013. Moscow: GEOTAR-
Media. 
2. Devyatova EA, Tsaturova KA, Vartanyan EV. 
Predicting of Successful Implantation at IVF 
cycles. Gynecological Endocrinology. 2016; 32 
(1): 27-29. 
3. Gajdukov SN, Boyarskij YuK, Pal`chenko NA. 
[Modern 4th Edition view on the problem of 
receptivity and thin endometrium in art programs 
(literature review)] [Published in Russian: 
Современный взгляд на проблему 
рецептивности и тонкого эндометрия в 
программах ВРТ (обзор литературы)]. Russian 
Journal of Human Reproduction. 2013; 4: 51-60.  
4. Nosenko EN, Saenko AI, Postolyuk IG. Receptor 
status of endometrium in infertile women with a 
history of unsuccessful attempts of assisted 
reproductive technologies [Published in Russian: 
Рецепторный статус эндометрия у 
бесплодных женщин с неудачными 
попытками вспомогательных 
репродуктивных технологий в анамнезе]. 
Tavricheskiy Mediko-Biologicheskiy Vestnik, 
2013; 16 (2;2): 80-82. 
5. Paulson RJ. Hormonal induction of endometrial 
receptivity. Fertility Sterility. 2011; 96(3):530–
535. 
6. Roque M, Valle M, Guimarães F, Sampaio M, 
Geber S. Freeze-All Policy: Fresh vs Frozen-
Thawed Embryo Transfer. FertilSteril. 2015; 
103:1190-1193. 
7. Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, 
Gómez E, Fernández-Sánchez M, Carranza F, 
Carrera J, Felip Vilella F, Pellicer A, Simón C. 
The endometrial receptivity array for diagnosis 
and personalized embryo transfer as a treatment 
for patients with repeated implantation failure. 
FertilSteril. 2013; 100(3): 818-824. 
8. Simon A, Laufer N. Assessment and treatment of 
repeated implantation failure (RIF). J Assist 
Reprod Genet. 2012; 29(11): 1227–1239. 
9. Bertram K, Anthony T, Susan M. 2009. Basic 
and Clinical Pharmacology, 11th Edition. New 
York: McGraw-Hill Medical. 
10. Tehraninejad ES, Kabodmehri R, Rashidi BH, 
Jafarabadi M, Keikha F, Masomi M, Hagholahi 
F. Transdermal estrogen (oestrogel) for 
endometrial preparation in freeze embryo 
transfer cycle: An RCT. Int J Reprod Biomed 
(Yazd). 2018; 16(1): P. 51-56. 
11. Mazur MT, Kurman RJ. Diagnostic of 
Endometrial Biopsies and Curreting: A Practical 
Approach. 2005. New York: Springer.  
12. Dabbs DJ. 2013. Diagnostic 
Immunohistochemistry: Theranostic and 
Genomic Applications, 4th Edition. Philadelphia, 
PA: Elsevier. 
13. Mikhail G, Wu CH, Ferin M, Vande Wiele RL. 
Radioimmunoassay of plasma estrone and 
estradiol. Steroids. 1970; 15(3): 333-352. 
14. Altman DG, Machin D, Bryant TN, Gardner MJ. 
2003. Statistics with Confidence. Confidence 
Intervals and Statistical Guidelines. Bristol: BMJ 
Books.  
